Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists

被引:17
作者
Han, XJ
Michne, JA
Pin, SS
Burris, KD
Balanda, LA
Fung, LK
Fiedler, T
Browman, KE
Taber, MT
Zhang, J
Dubowchik, GM
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
[2] AstraZeneca R&D Boston, Infect Discovery, Waltham, MA 02451 USA
[3] Palatin Technol Inc, Cranbury, NJ 08512 USA
[4] Neurogen Corp, Branford, CT 06405 USA
[5] Abbott Labs, Dept R4N5, Abbott Pk, IL 60064 USA
[6] Sanofi Aventis, Bridgewater, NJ 08807 USA
关键词
corticotropin-releasing factor 1 receptor antagonists; SAR; anxiolytic activity; mouse canopy model;
D O I
10.1016/j.bmcl.2005.05.117
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
7-Aryl-6,7-dihydroimidazoimidazoles represent a novel series of high-affinity corticotropin-releasing factor I receptor antagonists. Here, we report their synthesis and SAR as well as behavioral activity of two exemplary compounds, 7b and 7k, in a mouse canopy model of anxiety. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3870 / 3873
页数:4
相关论文
共 20 条
  • [1] Anisimova VA, 1999, PHARM CHEM J, V33, P361, DOI DOI 10.1007/BF02508707
  • [2] SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND IMMUNE-MEDIATED INFLAMMATION
    CHROUSOS, GP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) : 1351 - 1362
  • [3] Functional corticotropin-releasing factor receptors in human neuroblastoma cells
    Dieterich, KD
    DeSouza, EB
    [J]. BRAIN RESEARCH, 1996, 733 (01) : 113 - 118
  • [4] 2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists:: Synthesis, binding studies and behavioral efficacy
    Dubowchik, GM
    Michne, JA
    Zuev, D
    Schwartz, W
    Scola, PM
    James, CA
    Ruediger, EH
    Pin, SS
    Burris, KD
    Balanda, LA
    Gao, Q
    Wu, DD
    Fung, L
    Fiedler, T
    Browman, KE
    Taber, MT
    Zhang, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) : 3997 - 4000
  • [5] Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
    Gilligan, PJ
    Robertson, DW
    Zaczek, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) : 1641 - 1660
  • [6] GILLIGAN PJ, 2000, 219 ACS NAT M SAN FR
  • [7] Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats
    Grewal, SS
    Shepherd, JK
    Bill, DJ
    Fletcher, A
    Dourish, CT
    [J]. PSYCHOPHARMACOLOGY, 1997, 133 (01) : 29 - 38
  • [8] Grigoriadis Dimitri E., 2001, Current Medicinal Chemistry - Central Nervous System Agents, V1, P63, DOI 10.2174/1568015013358734
  • [9] International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands
    Hauger, RL
    Grigoriadis, DE
    Dallman, MF
    Plotsky, PM
    Vale, WW
    Dautzenberg, FM
    [J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 21 - 26
  • [10] Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding
    Heidempergher, F
    Pillan, A
    Pinciroli, V
    Vaghi, F
    Arrigoni, C
    Bolis, G
    Caccia, C
    Dho, L
    McArthur, R
    Varasi, M
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (21) : 3369 - 3380